Search bioRxiv⌕ Search

Biology subjects

Prier, A.

Publications and source records attributed to Prier, A..

2 recordsLinked to original sources

A biomathematical approaches models to identify human platelet activation signature in response to various agonists

BackgroundPlatelets are crucial mediators at the crossroads of hemostasis, immunity, and inflammation, adapting their responses to diverse stimuli. Despite their recognized role, the precise pathways and markers associated with platelet activation remain poorly understood. This study aimed to unravel these mechanisms by evaluating platelet responses to various agonists, employing biomathematical models to map activation patterns and identify key biomarkers. MethodsUsing samples from ten healthy donors, platelets were exposed to seven stimulation conditions: unstimulated, PAR-1 agonist TRAP, PAR-4 agonist AYPGKF, ADP, collagen, sCD40L, and fibrinogen. A comprehensive analysis of 47 biological markers--covering membrane activation, soluble mediators, and signaling pathways--was conducted. Statistical and machine learning models, including hierarchical clustering and random forests, were applied to classify and interpret platelet activation signatures. ResultsDistinct activation profiles were observed for each agonist. A streamlined panel of six markers--AKT, CD40 ligand, CD62P (mean fluorescence intensity and percentage), PKC, RANTES, and TSLP--achieved 86.8% accuracy in identifying the activating stimulus. The study highlighted significant variations, influenced by both the stimulus and donor-specific factors. Machine learning approaches further refined classification, achieving a multiclass accuracy of 87.9%. Hierarchical clustering demonstrated clear distinctions, particularly between PAR-1/PAR-4 responses and other agonists. ConclusionThis innovative research redefines platelets as dynamic "biological sensors" capable of decoding complex danger signals. By integrating biomathematical modeling and artificial intelligence, it identifies a precise biomarker panel with transformative potential for diagnostics and therapies in inflammation and immune disorders. This work positions platelets not just as key players in hemostasis but as programmable agents for precision medicine, heralding a new era in adaptive, AI-driven healthcare solutions. Author SummaryPlatelets are often seen as simple players in blood clotting, but they do much more. They sit at the crossroads of hemostasis (stopping bleeding), innate immunity (our bodys first defense), and inflammation. They even influence adaptive immunity and play key roles in maintaining healthy blood vessels and contributing to disease. What makes platelets fascinating is their ability to respond quickly to their environment. They carry various receptors and release substances like growth factors, immune signals, clotting factors, RNA, and tiny vesicles. This helps them react to threats and communicate with other cells. But the big question is: can platelets tailor their response based on specific stimuli? In my research, I set out to answer this. Using mathematical models and analytical techniques, I studied how platelets react to different triggers, especially those linked to immune and clotting responses. My goal was to identify specific molecular "signatures" that define how platelets respond. I found that platelets can distinguish between danger signals and adjust their secretory responses. Normally, this helps manage threats efficiently. However, when this response exceeds whats needed, it can contribute to diseases like cardiovascular disorders, severe infections, autoimmune conditions, and cancer. Understanding these pathways opens new doors for treatment. Since platelet activity can be influenced by drugs, we could shift their role from harmful to beneficial in many diseases. This could revolutionize how we approach conditions driven by inflammation and immune dysregulation. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/636809v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@9d9b5forg.highwire.dtl.DTLVardef@1438071org.highwire.dtl.DTLVardef@a59b29org.highwire.dtl.DTLVardef@6dd66b_HPS_FORMAT_FIGEXP M_FIG C_FIG

cell biology↗

Evaluation of in vitro activity of copper gluconate against SARS-CoV-2 using confocal microscopy-based high content screening

ContextSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that emerged late in 2019 is the etiologic agent of coronavirus disease 2019 (Covid-19). There is an urgent need to develop curative and preventive therapeutics to limit the current pandemic and to prevent the re-emergence of Covid-19. This study aimed to assess the in vitro activity of copper gluconate against SRAS-CoV-2. MethodsVero E6 cells were treated with copper gluconate 18 hours before infection. Cells were infected with a recombinant GFP expressing SARS-CoV-2. Infected cells were maintained in fresh medium containing copper gluconate for an additional 48-hour period. The infection level was measured by the confocal microscopy-based high content screening method. The cell viability in presence of copper gluconate was assessed by XTT assay. ResultsThe viability of Vero E6 cells treated with copper gluconate up to 200 M was found to be similar to that of untreated cells, but it dropped below 40% with 400 M of this agent. The infection rate was 23.8%, 18.9%, 20.6%, 6.9%, 5.3%,5.2% in cells treated with 0, 2, 10, 25, 50 and 100 M of copper gluconate respectively. As compared to untreated cells, the number of infected cells was reduced by 71%, 77%, and 78% with 25, 50, and 100 M of copper gluconate respectively (p < 0.05). ConclusionCopper gluconate was found to mitigate SARS-CoV-2 infection in Vero E6 cells. Furthers studies are needed to determine whether copper homeostasis could play a role in SARS-CoV-2 infection. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=76 SRC="FIGDIR/small/422548v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@1f99949org.highwire.dtl.DTLVardef@1bebae6org.highwire.dtl.DTLVardef@e05e37org.highwire.dtl.DTLVardef@49a3b2_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗